Abstract | Rationale:
Fibrosis leads to failure of the skin, lungs, and other organs in systemic sclerosis; accounts for substantial morbidity and mortality; and lacks effective therapy. Myofibroblast activation underlies organ fibrosis, but the key extracellular cues driving persistence of the process remain incompletely characterized. Objectives: The objectives were to evaluate activation of the IL6/JAK/STAT axis associated with fibrosis in skin and lung biopsies from systemic sclerosis patients and effects of the Food and Drug Administration-approved JAK/STAT inhibitor, tofacitinib, on skin and lung fibrosis in animal models. Methods: Conclusion:
|
Authors | Wenxia Wang, Swati Bhattacharyya, Roberta Goncalves Marangoni, Mary Carns, Kathleen Dennis-Aren, Anjana Yeldandi, Jun Wei, John Varga |
Journal | Journal of scleroderma and related disorders
(J Scleroderma Relat Disord)
Vol. 5
Issue 1
Pg. 40-50
(Feb 2020)
ISSN: 2397-1991 [Electronic] England |
PMID | 35382402
(Publication Type: Journal Article)
|
Copyright | © The Author(s) 2019. |